Creativity
Psychedelics have emerged as potential enhancers of creativity, influencing both divergent and convergent thinking processes. Current research indicates their capacity to disrupt cognitive rigidity and promote innovative thought patterns, warranting further exploration into their therapeutic and recreational applications.
Key Insights
- 1
Psychedelics enhance flexibility in thought by disrupting the DMN, promoting divergent thinking leading to innovative solutions.
- 2
Flexible thinking fostered by psychedelics has potential therapeutic applications for anxiety and depression.
- 3
Microdosing psychedelics has shown promise in boosting creativity, although results remain inconsistent across studies.
- 4
Acute use of psychedelics can enhance divergent thinking, but may impair structured problem-solving abilities.
What is Creativity?
Creativity is a multifaceted cognitive process that encompasses the generation of novel and valuable ideas and solutions. It involves two primary cognitive styles: divergent thinking, which fosters the production of multiple ideas, and convergent thinking, which narrows down these ideas to focus on a specific solution.
The Default Mode Network (DMN) plays a crucial role in creative thinking, as it is involved in self-referential and imaginative processes. Psychedelics may enhance creativity by disrupting normal DMN activity, leading to increased connectivity across different brain regions, thereby facilitating cognitive flexibility and spontaneity.
Personality traits, notably openness, are significant predictors of creative potential. Individuals with high levels of openness are more likely to explore new ideas, which aligns with the enhancing effects of psychedelics on divergent thinking.
Current Treatments
Standard treatments for enhancing creativity include traditional methods such as brainstorming sessions, cognitive training, and engaging in diverse creative activities like the arts. Pharmacological interventions are limited, with some examples being stimulant medications that may improve cognitive performance.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Creativity.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Research indicates mixed effects on creative performance with both improvements and null effects reported. | Medium | Moderate | Inconsistent |
| LSD LSD consistently enhances divergent thinking while sometimes impairing convergent problem-solving. | Medium | Moderate | Consistent |
| Ayahuasca Ayahuasca has shown promise in improving visual creativity and maintaining its effects after acute use. | Medium | Moderate | Consistent |
Psilocybin and Creativity
Psilocybin is reported to enhance divergent thinking and spontaneous creative insights, particularly following acute administration. Research shows that while immediate effects can vary, some individuals experience lasting increases in creativity, particularly in generating novel ideas.
LSD and Creativity
LSD facilitates a shift in cognitive processes, promoting greater novelty and originality in creative tasks. Users often report enhanced cognitive flexibility but may find structured task performance hindered during acute effects.
Ayahuasca and Creativity
Ayahuasca appears to affect creativity by enhancing visual and divergent thinking. Studies indicate that its effects can persist beyond the immediate experience, especially for visual creativity, following repeated ceremonial use.
Clinical Outlook
The future of psychedelic treatment for enhancing creativity looks promising, particularly in therapeutic settings where cognitive flexibility is crucial. Continued research will be essential to clarify the nuances of dosage, setting, and individual variability in experiences with psychoactive substances.
Industrial Landscape
Key figures in psychedelic creativity research include Kim Kuypers, who focuses on the neurobiology of flexible cognition, and Natasha Mason, who studies the cognitive mechanisms underlying psychedelics. Influential author James Fadiman has also contributed significantly to the discourse on psychedelics and creativity.
Quick Indicators
Organisations
Search →Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Johns Hopkins University
The Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
National Council of Scientific and Technical Research, Argentina
The National Council of Scientific and Technical Research (CONICET; Consejo Nacional de Investigaciones Científicas y Técnicas) is Argentina’s principal government agency for promoting science and technology, funding over 11,000 researchers and 10,000 doctoral students across a nationwide network of research institutes and centres. CONICET supported the NATMICRO study, a naturalistic observational investigation of the psychological and cognitive effects of self-administered psilocybin microdosing conducted in Argentina.
People
Search →Federico Cavanna
Researcher in psychedelic science / neuroscientific researcher (exact current title not confidently verified)
He is a coauthor on multiple widely cited studies on psilocybin microdosing, DMT, and psychedelic use, helping characterize subjective, behavioral, and cognitive effects of psychedelics.
Robin Murphy
Researcher at the University of Auckland School of Pharmacy
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Michiel Van Elk
Associate Professor of Cognitive Psychology at Leiden University
Michiel van Elk is a prominent psychedelic science researcher known for rigorous, skeptical work on psilocybin, microdosing, expectancy effects, and the psychological mechanisms and risks of psychedelic experiences.
Kate Godfrey
Research Associate at Imperial College London’s Centre for Psychedelic Research
Kate Godfrey is notable for contributing to leading human psychedelic research on microdosing, neuroimaging, and neuroplasticity at Imperial College London.
Anna Forsyth
Doctoral researcher / researcher at the University of Auckland
She is an author on multiple clinical studies of LSD microdosing in depression and related psychedelic psychiatry work, contributing to early human evidence on efficacy, tolerability, and mechanism.
Frederick Sundram
Associate Professor and Deputy Head of the Department of Psychological Medicine at the University of Auckland
He is a psychiatrist and clinical researcher contributing to psychedelic and novel-antidepressant studies, including LSD microdosing and ketamine/depression research.
Valerie Bonnelle
Scientific Assistant to the Director at the Beckley Foundation
She is a researcher coordinating psychedelic studies on microdosing, pain, autonomic physiology, and peak experiences, contributing to the clinical and mechanistic understanding of psychedelic effects.
Laura Alethia de la Fuente
Postdoctoral researcher in neuroscience at CONICET / Instituto de Física de Buenos Aires (IFIBA-UBA)
She co-authored several notable human psychedelic studies on psilocybin microdosing, DMT, and acute psilocybin effects, contributing both behavioral and neurophysiological evidence in the field.
Heith Copes
Professor of Criminal Justice at the University of Alabama at Birmingham
Heith Copes is a criminologist whose research connects drug use, identity, and narrative meaning, including multiple collaborations on classic psychedelics, microdosing, and related social/behavioral outcomes.
Matthew Baggot
Neuroscientist and CEO of Tactogen
He is a leading MDMA/entactogen researcher whose work has helped characterize the drug’s effects on emotion, social behavior, and therapeutic potential in humans.
Lilian Kloft
PhD candidate / researcher at Maastricht University
She is a psychopharmacology and forensic psychology researcher contributing to human studies on ayahuasca, MDMA, memory, and psychedelic-related brain and cognitive effects.
Connected Evidence
The latest clinical data and verified academic findings associated with Creativity.